Novartis' MenB vaccine Bexsero set for blockbuster status after new data
This article was originally published in Scrip
Executive Summary
Data presented this week indicate that Novartis's novel meningococcal B vaccine Bexsero has the potential to fill the one unmet need that remains in the meningococcal space – a safe vaccine with broad efficacy against serogroup B infections. Critics have been concerned that Bexsero causes increased rates of fever, but these fears were dampened by additional results presented at the World Vaccines Congress in Washington DC, paving the way for Bexsero to become Novartis's next big blockbuster.
You may also be interested in...
FDA taskforce: helpful guide or obstructive box-ticker?
Prompted by a diminishing pipeline, the FDA has formed a new taskforce to support the development of antibacterial drugs. While this is a positive move, there are questions as to whether this is a serious refocus or simply another case of rehashing FDA guidances to produce unfeasible clinical trials that have previously caused promising - and effective - drugs to be lost or stuck in the pipeline.
MenAfriVac: A 40 cent shot to clean up meningitis in Africa
The new MenAfriVac vaccine has dramatically reduced meningitis A rates in Africa. Data presented at the World Vaccines Congress (11-12 April 2012) by the Meningitis Vaccine Project revealed both a dramatic reduction in the overall number of meningitis cases, and an even more dramatic reduction in the incidence of disease caused by meningococcal A strain.
Phase II data from BiondVax heat up race for first universal flu vaccine
Data presented at the World Vaccines Congress by BiondVax suggest that the quest to develop a universal flu vaccine may soon be concluded.